Publication:
Role of isocitrate dehydrogenase 1/2 (IDH 1/2) gene mutations in human tumors

Thumbnail Image
Files
Liu-30-1155-1160-2015.pdf(572.01 KB)
Date
2015
relationships.isAuthorOfPublication
relationships.isSecondaryAuthorOf
relationships.isDirectorOf
Authors
Liu, Xiang ; Ling, Zhi-Qiang
item.page.secondaryauthor
item.page.director
Publisher
F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
10.14670/HH-11-643
item.page.type
info:eu-repo/semantics/article
Description
Abstract
In recent years, frequent isocitrate dehydrogenase 1/2 (IDH1/IDH2) gene mutations were found in a variety of tumors, which specifically alter arginine residues of catalytic active site in IDH1/IDH2 and confer new enzymatic function of directly catalyzing alpha-ketoglutarate (α-KG) to R-2-hydroxyglutarate (2- HG). 2-HG could competitively inhibit α-KG–dependent enzymes and might therefore contribute to tumorigenesis. In addition, mutation status of IDH1/IDH2 is closely related to the progress and prognosis of certain tumors. Thus IDH1/IDH2 is considered to be a promising biomarker for early diagnosis and prognosis and targeted therapy. In this study, the current research on IDH1/IDH2 mutation, especially the mechanisms and clinical characteristics related to tumor, are reviewed.
publication.page.subject
Isocitrate dehydrogenase 1/2 (IDH1/IDH2) , Mutations , Methylation , Metabolism , Tumorigenesis
Citation
Histology and histopathology, Vol. 30, nº10, (2015)
URI
http://hdl.handle.net/10201/100050
item.page.embargo
Collections
Histology and histopathology Vol.30,nº10 (2015)
Ir a Estadísticas